Drug Trial Radar · NCT06647745
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
222
Actual
Start
Apr 10, 2025
Primary completion
Nov 4, 2026
Study completion Jan 28, 2027
Sponsor
- Lead sponsor
- THPharm Corp.Industry
- Sponsor type
- Industry
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
\[Primary Objective\] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102 (telmisartan 80 mg) compared to THP-00101 or THP-00102 monotherapy among subjects with type 2 diabetes mellitus accompanied by essential hypertension. \[Secondary Objective\] To comparatively evaluate secondary efficacy and safety in the THP-00101 monotherapy group, THP-00102 monotherapy group, THP-00101 and THP-00102 combination therapy group, and THP-00101 and THP-00103 (telmisartan 40 mg) combination therapy group among subjects with type 2 diabetes mellitus accompanied by essential hypertension.
Conditions
- Type 2 Diabetes
- Hypertension
Interventions
THP-00101Drug
Dapagliflozin 10 mg
THP-00102Drug
Telmisartan 80 mg
THP-00103Drug
Telmisartan 40 mg
THP-00104Drug
Placebo of Dapagliflozin 10mg
THP-00105Drug
Placebo of Telmisartan 80mg
THP-00106Drug
Placebo of Telmisartan 40mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Hemoglobin A1c (HbA1c)Time frame: 12 weeks
- Changes in Mean Sitting Systolic Blood Pressure (MSSBP)Time frame: 12 Weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
The Catholic University of Korea, Yeouido ST. Mary's Hospital
Seoul, South Korea
Thammasat University Hospital
Pathum Thani, Changwat Pathum Thani, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.